



01-09-12

PATENT

Customer No. 23630

Attorney Docket No. 068911-0169

In The United States Patent And Trademark Office

In re Application of:

Babish et al.

Application No.: 10/590,301

Filed: August 23, 2006


For: SYNERGISTIC ANTI-INFLAMMATORY
PHARMACEUTICAL COMPOSITIONS
AND METHODS OF USE

)
)
) Group Art Unit: 1627
)
) Examiner: Kanthamneni, Shobha
)
) Confirmation No.: 7158

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the U.S. Postal Service via Express Mail Label No. EV643770991US, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or facsimile transmitted (571-273-8300) to the USPTO on the date indicated below.

Date: January 6, 2012


Jacqueline Andreu

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


TRANSMITTAL LETTER

Enclosed for filing in connection with the above-referenced patent application are the following documents:

- 1) Information Disclosure Statement (2 pages);
- 2) Information Disclosure Citation in an Application (PTO Form 1449) (4 pages);
- 3) References cited in IDS by Applicant (B1-B2) and (C1-C44); and
- 4) Return Receipt Postcard.

No fee is believed to be due in connection with the filing of this disclosure. However, please charge any necessary fees to our Deposit Account No. 50-1133.

Respectfully submitted,



Atabak R. Royae, Reg. No.: 59,037
McDermott Will & Emery LLP
28 State Street
Boston, MA 02109-1775
Telephone: (617) 535-4108
Facsimile: (617) 535-3800

Date: January 6, 2012



PATENT
Customer No. 23630
Attorney Docket No. 068911-0169


In The United States Patent And Trademark Office

In re Application of:)
)
Babish et al.) Group Art Unit: 1627
)
Application No.: 10/590,301) Examiner: Kanthamneni, Shobha
)
Filed: August 23, 2006) Confirmation No.: 7158
)
For: SYNERGISTIC ANTI-INFLAMMATORY)
PHARMACEUTICAL COMPOSITIONS)
AND METHODS OF USE)

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the U.S. Postal Service via Express Mail Label No. EV643770991US, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or facsimile transmitted (571-273-8300) to the USPTO on the date indicated below.

Date: January 6, 2012


Jacqueline Andreu

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed after filing an RCE (dated 02/22/2011) in the above-referenced application; therefore, no fee is believed to be due with the filing of this IDS.


This Statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, the Applicant understands that the Examiner will make an independent evaluation of the cited publications.

If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited document does not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents. Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 50-1133 and please credit any excess fees to such deposit account.

Respectfully submitted,

McDERMOTT WILL & EMERY LLP




Atabak R. Royace
Registration No. 59,037
28 State Street
Boston, MA 02109
Phone: 617-535-4108
Facsimile: 617-535-3800
Date: January 6, 2012

**Please recognize our Customer No. 23630
as our correspondence address.**

SHEET 1 OF 4

(PTO-1449)



U.S. PATENT DOCUMENTS

[illegible]

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)		ATTY. DOCKET NO. 068911-0169		SERIAL NO. 10/590,301	
		APPLICANT Babish et al.			
		FILING DATE Aug. 23, 2006		GROUP 1627	
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)					
EXAMINER'S INITIALS	CITE NO. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			2
	C1	Buhler et al., Antioxidant Activities of Flavanoids, 3 pages, 11/2000			
	C2	European Examination Report for EP App. No. 02748188.6-1216			
	C3	European Search Report EP 10006768			
	C4	European Search Report EP 10011254			
	C5	European Search Report EP 10013109			
	C6	European Search Report EP 10162893			
	C7	European Search Report for EP App. No. 07809709.4			
	C8	Gerhauser et al., Molecular Cancer Therapeutics Vol. 1, No. 11, pp:959-969 (2002)			
	C9	Haridradilepah 01, TKDL, 1 August 1999, XP003024376, (3 pages)			
	C10	Kuo et al., Cancer Letter, 203:127-137 (2004)			
	C11	Lukaczer et al., Phytotherapy Research, Vol. 19, No. 10, pp:864-869 (2005)			
	C12	Murvadyaghtam, TKDL, 1 January 1990, XP003024379 (4 pages)			
	C13	Murvadyaghtam, TKDL, 1 January 2001, XP003024377 (4 pages)			
	C14	Office Action issued in U.S. App. No. 10/464,410 (068911-0023) on 05/23/2011			
	C15	Office Action issued in U.S. App. No. 10/532,388 (068911-0116) on 06/28/2011			
	C16	Office Action issued in U.S. App. No. 10/532,388 (068911-0116) on 10/01/2010			
	C17	Office Action issued in U.S. App. No. 10/789,814 (068911-0075) on 03/18/2011			
	C18	Office Action issued in U.S. App. No. 11/344,555 (068911-0141) on 01/19/2011			
	C19	Office Action issued in U.S. App. No. 11/501,393 (068911-0150) on 11/09/2011			
	C20	Office Action issued in U.S. App. No. 11/636,867 (068911-0172) on 03/08/2011			
	C21	Office Action issued in U.S. App. No. 11/636,867 (068911-0172) on 10/28/2011			
	C22	Office Action issued in U.S. App. No. 11/729,696 (068911-0180) on 07/14/2011			
	C23	Office Action issued in U.S. App. No. 11/729,696 (068911-0180) on 11/01/2010			
	C24	Office Action issued in U.S. App. No. 11/820,600 (068911-0214) on 05/26/2011			
	C25	Office Action issued in U.S. App. No. 11/820,600 (068911-0214) on 09/30/2010			
	C26	Office Action issued in U.S. App. No. 11/820,607 (068911-0220) on 05/23/2011			
	C27	Office Action issued in U.S. App. No. 11/820,607 (068911-0220) on 10/12/2010			
	C28	Office Action issued in U.S. App. No. 11/820,653 (068911-0211) on 08/08/2011			
	C29	Office Action issued in U.S. App. No. 11/820,755 (068911-0205) on 06/01/2011			
	C30	Office Action issued in U.S. App. No. 11/820,755 (068911-0205) on 10/18/2010			
	C31	Office Action issued in U.S. App. No. 12/048,613 (068911-0240) on 12/08/2010			
	C32	Office Action issued in U.S. App. No. 12/331,887 (068911-0276) on Oct122011			
	C33	Office Action issued in U.S. App. No. 12/626,392 (068911-0337) on 07/08/2011			
EXAMINER		DATE CONSIDERED			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.